CTHRC1 drives megakaryocyte-mediated immunotherapy resistance in esophageal squamous cell carcinoma via the integrin αIIbβ3/Rap1 pathway and is targetable by mRNA vaccination.
Liu Y; Zhou J; Song M; Wang J; Shang Q; Du J; Li Y; Chen X; Wang J; Liao X; Chen L; Li W; Yuan Y; Yang Y; Wu Y
Scientists found that a protein called CTHRC1 makes medicine for fighting esophagus cancer less effective because it helps make the cancer harder to attack. They made a special vaccine to stop CTHRC1, which helped the medicine work better and shrink the cancer in tests. This discovery gives hope for better treatments in the future.